Patients with CXCR4 mutations present with a significantly lower rate of adenopathy, and those with CXCR4 nonsense mutations have increased bone marrow disease, serum IgM levels, and/or symptomatic hyperviscosity. This evidence concerns the gene CXCR4 and bone marrow disorder.